Severe Inflammatory Ophthalmopathy in a Euthyroid Patient during Nivolumab Treatment

Conclusion: We report severe inflammatory ophthalmopathy in a euthyroid patient with non-small-cell lung cancer during nivolumab therapy. The occurrence of such ophthalmic adverse events is likely to increase during nivolumab therapy in patients with advanced malignancies.Eur Thyroid J

Source: European Thyroid Journal - January 4, 2018 Category: Endocrinology Source Type: research